Rectal Cancer Clinical Trial
Official title:
An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Verified date | September 2012 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
Status | Completed |
Enrollment | 119 |
Est. completion date | December 2011 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
For complete inclusion and exclusion criteria, please refer to the investigator. Inclusion
Criteria 1. Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved informed consent form 2. Diagnosis of metastatic colorectal adenocarcinoma (may have received 1 prior chemotherapy regimen for metastatic CRC) 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4. Adequate hematological function 5. Adequate renal function 6. Adequate hepatic function 7. Life expectancy of greater than or equal to 3 months as documented by the investigator Exclusion Criteria: 1. More than 1 prior chemotherapy regimen for metastatic CRC 2. Central nervous system (CNS) metastases 3. History of venous thrombosis 4. Myocardial infarction, cerebrovascular accident, transient ischemic attack, grade 2 or greater peripheral vascular disease, congestive heart failure, ongoing arrhythmias requiring medication, or unstable angina within 1 year before study enrollment 5. History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on screening chest computed tomograph (CT) scan 6. Average systolic blood pressure > 150mm Hg or average diastolic blood pressure of > 90mm Hg 7. Radiotherapy within 28 days of study enrollment or within 14 days of study enrollment for peripheral lesions 8. Prior AMG 706, oral inhibitors of AMG706, panitumumab, or another anti-EGFr monoclonal antibody (mAb) (e.g., cetuximab [Erbitux®] or EMD 72000) 9. Systemic chemotherapy within 28 days before study enrollment 10. Major surgery within 28 days or minor surgery within 7days of study enrollment 11. History of life threatening ventricular arrhythmia (eg, sustained ventricular tachycardia) 12. Female and male subjects of childbearing potential not using adequate contraceptive precautions 13. Participation in therapeutic clinical trials within 30 days before study enrollment 14. Not recovered from all previous therapies 15. Clinically significant open would, ulcer or fracture 16. Any co-morbid medical condition that would increase the risk of toxicity |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Amgen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1a - The incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities | First 2 cycles | Yes | |
Primary | Part 1b - The incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities | First 2 cycles | Yes | |
Primary | Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen | Every 8 weeks (+/- 7 days) | No | |
Secondary | Part 1a - The PK of irinotecan (and its active metabolite SN38) when administered as a part of the FOLFIRI regimen with panitumumab and AMG 706 | Cycle 1 and 2 (Days 1, 2, 3) | No | |
Secondary | Part 1a - The PK of oxaliplatin when administered as a part of the FOLFOX-4 regimen with panitumumab and AMG 706 | Cycle 1 and 2 (Day 1) | No | |
Secondary | Part 1a - The objective tumor response rate (complete and partial response) throughout the study | Every 6 to 8 weeks | No | |
Secondary | Part 1b - The incidence of adverse events and clinical laboratory abnormalities not defined as dose-limiting toxicities | Every visit | Yes | |
Secondary | Part 1b - The PK of AMG 706 when administered with either the FOLFIRI or FOLFOX-4 chemotherapy regimen | Cycle 2 (Day 1-2), Cycle 3 (Day 1) | No | |
Secondary | Part 1b - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with AMG 706 | Cycle 1 and 2 (Day 3) | No | |
Secondary | Part 2 - Duration of response: (Calculated for only those subjects who respond) | Time from first objective tumor response (subsequently confirmed at least 4 weeks later) to objective disease progression or death. | No | |
Secondary | Part 2 - Time-to-progression | Time from first dose of investigational product to objective disease progression or death due to disease progression. | No | |
Secondary | Part 1b - The PK of irinotecan (and its active metabolite SN38) when administered as a part of the FOLFIRI regimen with AMG 706 | Cycle 1 and 2 (Days 1, 2, 3) | No | |
Secondary | Part 1b- The PK of oxaliplatin when administered as a part of the FOLFOX-4 regimen with AMG 706 | Cycle 1 and 2 (Day 1) | No | |
Secondary | Part 1b - The objective tumor response rate (complete and partial response) throughout the study | Every 8 weeks (+/- 7 days) | No | |
Secondary | Part 2 - Overall survival | Time from first dose of investigational product to death. Subjects who have not died while on study or are lost to follow-up will be censored at their last contact date. (Time on study plus 36 months of long term follow-up) | No | |
Secondary | Part 2 - The incidence of adverse events and clinical laboratory abnormalities | Every visit | Yes | |
Secondary | Part 2 - The PK of AMG 706 when administered with either the FOLFIRI or FOLFOX-4 chemotherapy regimen (at a subset of the study centers with the capabilities to draw, ship and process PK samples) | Cycles 2, 4, 7, and every 3 subsequent cycles (Day 1) | No | |
Secondary | Exploratory - Potential biomarker development based on assessment of blood cells, tumor cells, and urine and the proposed mechanism of action of study drugs, and response | Day 1 of cycles 1 and 2, and within 7 days of a radiographic assessment | No | |
Secondary | Exploratory - The effects of genetic variation in drug metabolism genes, cancer genes, and drug target genes on subject response to investigational products (separate informed consent) | Day 1 of cycles 1 and 2, and within 7 days of a radiographic assessment | No | |
Secondary | Part 2 - Progression-free survival time | Time from first dose of investigational product to objective disease progression or death, subjects who have not progressed or died while on study will be censored at their last evaluable assessment date. | No | |
Secondary | Part 2 - Incidence of subjects undergoing resection of metastases for curative intent | As needed | Yes | |
Secondary | Part 1a - The incidence of adverse events and clinical laboratory abnormalities not defined as dose-limiting toxicities | Every visit | Yes | |
Secondary | Part 1a - The PK of AMG 706 when administered with panitumumab and either the FOLFIRI or FOLFOX-4 chemotherapy regimen | Cycle 2 (Day 1-2), Cycle 3 (Day 1) | No | |
Secondary | Part 1a - The serum concentration of panitumumab when administered with AMG 706 and either the FOLFIRI or FOLFOX-4 chemotherapy regimen | Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 4 (Day 1) | No | |
Secondary | Part 1a - The incidence of HAPA response following panitumumab administration | Cycle 1 (Day 1), Cycle 4 (Day 1), End of Study | Yes | |
Secondary | Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706 | Cycle 1 and 2 (Day 3) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |